Coreline Soft announced on the 28th that it will supply its artificial intelligence (AI) lung image pattern analysis software product, "AIVIEW Lung Texture," to the Taiwan subsidiary of the German company Boehringer Ingelheim.
AIVIEW Lung Texture is a product that analyzes chest computed tomography (CT) images in a few minutes to quantify and classify lung fibrosis patterns. The results can be integrated in real-time with the Picture Archiving and Communication System (PACS) and Radiology Information System (RIS), and can be immediately reviewed on a web-based dedicated viewer.
Boehringer Ingelheim plans to apply AIVIEW Lung Texture in major tertiary hospitals in Taiwan to accumulate real-world data on the approved anti-fibrotic drug "Ofev" (generic name nintedanib) and to conduct clinical validation of "Neratinib" simultaneously. This will target patients with interstitial lung disease (ILD) and interstitial lung abnormalities (ILA).
Coreline Soft aims to expand its collaboration with Boehringer Ingelheim regarding new drug development from this supply. The company stated that it will expand application to major hospitals across Taiwan through additional product supplies and operate it in the form of a screening program to promote the establishment of next-generation ILD treatment methods.
Kim Jin-guk, CEO of Coreline Soft, said, "Boehringer Ingelheim purchasing and distributing AIVIEW Lung Texture directly to major hospitals is a confirmation of the clinical reliability of Coreline Soft's AI technology," and added, "We will build a research ecosystem where early diagnosis and innovative treatments for ILD patients can be quickly applied."